329 related articles for article (PubMed ID: 26936230)
1. Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity.
Guo T; Woo SL; Guo X; Li H; Zheng J; Botchlett R; Liu M; Pei Y; Xu H; Cai Y; Zeng T; Chen L; Li X; Li Q; Xiao X; Huo Y; Wu C
Sci Rep; 2016 Mar; 6():22612. PubMed ID: 26936230
[TBL] [Abstract][Full Text] [Related]
2. Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.
Zhang YP; Deng YJ; Tang KR; Chen RS; Liang S; Liang YJ; Han L; Jin L; Liang ZE; Chen YN; Yang QH
Curr Med Sci; 2019 Feb; 39(1):37-43. PubMed ID: 30868489
[TBL] [Abstract][Full Text] [Related]
3. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
4. Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity.
Woo SL; Xu H; Li H; Zhao Y; Hu X; Zhao J; Guo X; Guo T; Botchlett R; Qi T; Pei Y; Zheng J; Xu Y; An X; Chen L; Chen L; Li Q; Xiao X; Huo Y; Wu C
PLoS One; 2014; 9(3):e91111. PubMed ID: 24638078
[TBL] [Abstract][Full Text] [Related]
5. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
[TBL] [Abstract][Full Text] [Related]
6. Berberine alleviates adipose tissue fibrosis by inducing AMP-activated kinase signaling in high-fat diet-induced obese mice.
Wang L; Ye X; Hua Y; Song Y
Biomed Pharmacother; 2018 Sep; 105():121-129. PubMed ID: 29852389
[TBL] [Abstract][Full Text] [Related]
7. Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3.
Xu X; Zhu XP; Bai JY; Xia P; Li Y; Lu Y; Li XY; Gao X
FASEB J; 2019 Jun; 33(6):7289-7300. PubMed ID: 30848932
[TBL] [Abstract][Full Text] [Related]
8. Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress.
Zhang Z; Li B; Meng X; Yao S; Jin L; Yang J; Wang J; Zhang H; Zhang Z; Cai D; Zhang Y; Ning G
Sci Rep; 2016 Feb; 6():20848. PubMed ID: 26857750
[TBL] [Abstract][Full Text] [Related]
9. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
[TBL] [Abstract][Full Text] [Related]
10. Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice.
Vida M; Gavito AL; Pavón FJ; Bautista D; Serrano A; Suarez J; Arrabal S; Decara J; Romero-Cuevas M; Rodríguez de Fonseca F; Baixeras E
Dis Model Mech; 2015 Jul; 8(7):721-31. PubMed ID: 26035386
[TBL] [Abstract][Full Text] [Related]
11. Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans.
Wu L; Xia M; Duan Y; Zhang L; Jiang H; Hu X; Yan H; Zhang Y; Gu Y; Shi H; Li J; Gao X; Li J
Cell Death Dis; 2019 Jun; 10(6):468. PubMed ID: 31197160
[TBL] [Abstract][Full Text] [Related]
12. ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis.
He Q; Mei D; Sha S; Fan S; Wang L; Dong M
J Mol Endocrinol; 2016 Nov; 57(4):251-260. PubMed ID: 27658958
[TBL] [Abstract][Full Text] [Related]
13. Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet.
Liou CJ; Lee YK; Ting NC; Chen YL; Shen SC; Wu SJ; Huang WC
Cells; 2019 May; 8(5):. PubMed ID: 31083505
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats.
Li QP; Dou YX; Huang ZW; Chen HB; Li YC; Chen JN; Liu YH; Huang XQ; Zeng HF; Yang XB; Su ZR; Xie JH
Phytomedicine; 2021 May; 85():153550. PubMed ID: 33831691
[TBL] [Abstract][Full Text] [Related]
15. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
[TBL] [Abstract][Full Text] [Related]
16. Berberine Ameliorates Abnormal Lipid Metabolism via the Adenosine Monophosphate-Activated Protein Kinase/Sirtuin 1 Pathway in Alcohol-Related Liver Disease.
Zhu L; Xu JJ; Li HD; Li JJ; Cheng M; Niu XN; Jia PC; Liu JY; Huang C; Lv XW; Li J
Lab Invest; 2023 Apr; 103(4):100041. PubMed ID: 36870291
[TBL] [Abstract][Full Text] [Related]
17. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
[TBL] [Abstract][Full Text] [Related]
18. Berberine alleviates hepatic lipid accumulation by increasing ABCA1 through the protein kinase C δ pathway.
Liang H; Wang Y
Biochem Biophys Res Commun; 2018 Apr; 498(3):473-480. PubMed ID: 29505790
[TBL] [Abstract][Full Text] [Related]
19. The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease.
Zhu X; Bian H; Gao X
Molecules; 2016 Oct; 21(10):. PubMed ID: 27754444
[TBL] [Abstract][Full Text] [Related]
20. Curcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinase.
Um MY; Hwang KH; Ahn J; Ha TY
Basic Clin Pharmacol Toxicol; 2013 Sep; 113(3):152-7. PubMed ID: 23574662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
